


#5

CERTIFICATE OF MAILING																			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231																			
Typed or Printed Name	Donna Macedo																		
Signature		Date	5/21/02																
CERTIFICATION REGARDING SEQUENCE LISTING		<table border="1"> <tr> <td>Attorney Docket</td> <td>BIOS-001</td> </tr> <tr> <td>First Named Inventor</td> <td>CHOU, QUIN</td> </tr> <tr> <td>Application Number</td> <td>10/087,229</td> </tr> <tr> <td>Filing Date</td> <td>February 27, 2002</td> </tr> <tr> <td>Confirmation Number</td> <td>6940</td> </tr> <tr> <td>Group Art Unit</td> <td>1635</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td colspan="2">Title: "METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME"</td> </tr> </table>		Attorney Docket	BIOS-001	First Named Inventor	CHOU, QUIN	Application Number	10/087,229	Filing Date	February 27, 2002	Confirmation Number	6940	Group Art Unit	1635	Examiner Name	Unassigned	Title: "METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME"	
Attorney Docket	BIOS-001																		
First Named Inventor	CHOU, QUIN																		
Application Number	10/087,229																		
Filing Date	February 27, 2002																		
Confirmation Number	6940																		
Group Art Unit	1635																		
Examiner Name	Unassigned																		
Title: "METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME"																			
Address to: BOX Missing Parts Commissioner for Patents Washington, D.C. 20231																			

Sir:

I hereby certify that the enclosed Sequence Listing is being submitted under 37 CFR §§ 1.821(c) and (e) in paper and computer readable form (Compact Disk labeled 'CRF').

As required by 37 CFR 1.821(f), I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same. The Computer Readable Format (CRF), being submitted under 37 CFR §§ 1.52(e) and 1.824, is formatted on IBM-PC, the operating system compatibility is MS-Windows and the file listing is:

Seqlist.txt 4.33 KB created May 20, 2002.

I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

Respectfully submitted,

Dated: 5.21.02

By:


Bret E. Field
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



#5

SEQUENCE LISTING

<110> Chou, Quin
Cabradilla, Cirilo D.

<120> Methods of Using FET Labeled
Oligonucleotides That Include a 3'-5' Exonuclease Resistant
Quencher Domain and Compositions for Practicing the Same

<130> BIOS-001

<140> 10/087,229
<141> 2002-02-27

<160> 22

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 1
ggtgttggag gagctttca g

21

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 2
ccagcctccg ttatcctgga

20

<210> 3
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 3
cctgtggatg actgagttacc tgaacct

27

<210> 4

<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 4
cctgtggatg actgagtaacc tgaaccg 27

<210> 5
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 5
cctgtggatg actgagtaacc tgaaccg 27

<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 6
cctgtggatg actgagtaacc tgaaccg 27

<210> 7
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 7
cctgtggatg actgagtaacc tgaaccg 27

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 8
gagctacgag ctgcctgac 19

<210> 9		
<211> 18		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> synthetic oligonucleotide		
<400> 9		
gactccatgc ccaggaag		18
<210> 10		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> synthetic oligonucleotide		
<400> 10		
catcaccatt ggcaatgagc g		21
<210> 11		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> synthetic oligonucleotide		
<400> 11		
catcaccatt ggcaatgagc g		21
<210> 12		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> synthetic oligonucleotide		
<400> 12		
catcaccatt ggcaatgagc g		21
<210> 13		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> synthetic oligonucleotide		
<400> 13		
catcaccatt ggcaatgagc g		21

<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 14
catcaccatt ggcaatgagc g

21

<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 15
cccaaaaatt cattatgctg caa

23

<210> 16
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 16
cagcattcca cgatatggat ttacggc

27

<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 17
cagcattcca cgatatggat ttacggc

27

<210> 18
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 18

atcagcattc cacgatatgg attacggca tcagttgcag cataatgaat ttttggga 58

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 19
ggaagaatgt gtcaggctca aag 23

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 20
ctgacacctgaa gcacttgaag gag 23

<210> 21
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 21
tgaaaatcggc tcccgca 17

<210> 22
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 22
tgaaaatcgac tcccgcaga 19